Categories
Colon Cancer

CRICKET and CAVE: Cetuximab for the treatment of mCRC [Video]

Erika Martinelli, MD, PhD, University of Campania Luigi Vanvitelli, Caserta, Italy, talks on findings from the CRICKET (NCT02296203) and CAVE (NCT04561336) trials. In the CRICKET trial, patients with KRAS, NRAS and BRAF wild-type, irinotecan-resistant metastatic colorectal cancer (mCRC) who were progressing after an initial response to a first-line cetuximab-containing therapy, received a rechallenge third-line treatment with cetuximab plus irinotecan. In the CAVE trial, the safety and efficacy of cetuximab plus avelumab, in patients with RAS wild-type (WT) mCRC treated in first line with chemotherapy in combination with an anti-EGFR drug, was assessed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

Categories
Breast Cancer

Stratifying patients with breast cancer by a 7-gene assay for endocrine therapy [Video]

Current strategies to identify patients with breast cancer who will benefit from radiotherapy or endocrine therapy have been ineffective, with various trials such as the RTOG 9804 trial (NCT00003857) have failed to elucidate the relevant subgroup of patients. Pat W. Whitworth, MD, Vanderbilt University Medical Center, Nashville, TN, describes the benefit of a 7-gene predictive ductal carcinoma in situ (DCIS) biosignature in discerning patients receiving breast conserving surgery (BCS) for DCIS who will benefit adjuvant endocrine therapy. The assay revealed that patients who had an elevated or residual risk were more likely to benefit from radiotherapy and endocrine therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Colon Cancer

Adding chemotherapy to immunotherapy in metastatic CRC [Video]

Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, presents data from the phase Ib KEYNOTE-651 trial (NCT03374254), which assessed pembrolizumab with modified FOLFOX7 or FOLFIRI in patients with metastatic colorectal cancer (mCRC). In two out of five cohorts, patients with microsatellite stable CRC were given first- or second-line pembrolizumab with modified FOLFOX7 or FOLFIRI and the progression-free survival (PFS) was found to be comparable to that of patients not receiving pembrolizumab. Dr Kim additionally discusses the efficacy of certain biomarkers such as PD-L1 levels and the mutational status of KRAS in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Pancreatic Cancer

New Insights from Mouse Models for Pancreatic, Breast and Colon Cancers [Video]

September 28, 2021Speakers: Zhiying Li, PhD and Steve Smith, PhDAccording to IARC, there were 9.96 million deaths in 2020 and cancer is the second- leading cause worldwide. To save lives, we need efficacious and safe therapeutics. To develop such therapeutics, we need animal models resembling human diseases for preclinical efficacy and safety studies. Mouse models are invaluable tools in this regard.In this webinar, Dr. Smith will share the most up-to-date data on GemPharmatech’s mouse models for pancreatic, breast and colon cancers. Key points include:1. KPC mouse model and drug efficacy testing using KPC cell line for pancreatic cancer R&D• Characteristics and treatment strategies of pancreatic cancer• KPC model construction strategy• Applications of Kras G12D and TP53 models2. MMTV-PyMT and APC min mouse models for breast and colon cancer research and drug developmentFor more information, please contact sales@atlantisbioscience.com#preclinicaloncology, #cancer, #breastcance, #coloncancer, #pancreaticcancer, #animalmodel, #KPC, #APCmin, #MMTY-PyMT, #Kras, #p53

Categories
Lung Cancer

GRACE Targeted Therapies Lung Cancer 2021 – Best Treatment Patient with a Designated KRAS Mutation [Video]

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty.In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss how a patient with a designated KRAS mutation ensures the best treatment. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentechFor more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.